EverPoint Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

EverPoint Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.43M	Buy	+200,000	New	+$2.19M	0.03%	350

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EverPoint Asset Management's SNDX Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in Syndax Pharmaceuticals (SNDX) in Q4 2016: 200,000 shares worth $1.43M. The stake represents 0.03% of the portfolio and ranks #350 among its holdings.

57 funds tracked by Wall St. Rank hold SNDX as of Q4 2016.

EverPoint Asset Management held 200,000 shares of Syndax Pharmaceuticals worth $1.43M as of Q4 2016.
Syndax Pharmaceuticals was a new EverPoint Asset Management position in Q4 2016.
Syndax Pharmaceuticals made up 0.03% of EverPoint Asset Management's portfolio in Q4 2016, its #350 holding.
57 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.